Doç. Dr. Özgür AÇIKGÖZ

1. Real-world Efficacy and Safety of Trastuzumab Deruxtecan in HER2-positive Metastatic Breast Cancer: A Multicenter Retrospective Study from Türkiye

MUĞLU H., SÜNGER E., ŞEKER CAN L., Han Ö., Güney B., HAMDARD J., et al.

Journal of Oncological Science , cilt.12, sa.1, ss.59-66, 2026 (Scopus, TRDizin)

2. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study

Mildanoglu M. M., Yucel M. H., Engin Delipoyraz E., SÜNGER E., ÖZÇELİK H., FİDAN S., et al.

Journal of Clinical Medicine , cilt.15, sa.6, 2026 (SCI-Expanded, Scopus)

3. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

Yildirim M. E., Karadurmuş N., Ökten İ. N., Türk H. M., Urakçı Z., Arslan Ç., et al.

Journal of Oncology Pharmacy Practice , cilt.31, sa.3, ss.404-411, 2025 (SCI-Expanded, Scopus)

4. Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes.

Yıldiz A., BİLİCİ A., AÇIKGÖZ Ö., HAMDARD J., BASIM P., ÇAKIR T., et al.

Journal of chemotherapy (Florence, Italy) , cilt.37, sa.1, ss.60-68, 2025 (SCI-Expanded, Scopus)

5. Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience

Hamdard J., Bilici A., Sakin A., Kahraman S., Yasin A. I., Kalaci E., et al.

Journal of Chemotherapy , cilt.37, sa.3, ss.268-277, 2025 (SCI-Expanded, Scopus)

6. Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer

Kutlu Y., Cekin R., Göktaş Aydın S., Shbair A. T. M., Bilici A., Arici S., et al.

CURRENT PROBLEMS IN CANCER , cilt.50, 2024 (SCI-Expanded, Scopus)

7. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.

Göktaş Aydın S., Ölmez Ö. F., Selvi O., Geredeli C., Özden F., Bilici A., et al.

Journal of gastrointestinal cancer , cilt.55, sa.1, ss.227-236, 2024 (ESCI, Scopus)

8. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

Yıldırım H. Ç., Kutlu Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., et al.

International Journal of Clinical Oncology , cilt.29, sa.3, ss.258-265, 2024 (SCI-Expanded, Scopus)

9. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

Goktas Aydin S., Kutlu Y., Muglu H., Aydin A., Acikgoz Ö., Hamdard J., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.93, ss.71-78, 2024 (SCI-Expanded, Scopus)

10. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Aydın S. G., Kavak E. E., Topcu A., Bayramgil A., Akgul F., Kahraman S., et al.

Biomolecules and Biomedicine , cilt.23, sa.6, ss.1089-1095, 2023 (Scopus)

11. Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer

GÖKTAŞ AYDIN S., BİLİCİ A., ÇALIŞ E., KUTLU Y., HAMDARD J., MUĞLU H., et al.

INTERNATIONAL IMMUNOPHARMACOLOGY , cilt.124, 2023 (SCI-Expanded, Scopus)

12. The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients

acikgoz o., Göktaş Aydın S., Bilici A., Kutlu Y., Muglu H., Karcı E., et al.

ACTA ONCOLOGICA TURCICA , cilt.56, sa.2, ss.153-160, 2023 (TRDizin)

13. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy

Kutlu Y., Aydin S. G., Bilici A., Oven B. B., Ölmez Ö. F., Açıkgöz Ö., et al.

Medicine (United States) , cilt.102, sa.15, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

14. SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT

Aydın S., Kutlu Y., Muglu H., Açıkgöz Ö., Aydın A., Bilici A., et al.

İstanbul Tıp Fakültesi Dergisi , cilt.86, sa.2, ss.117-122, 2023 (ESCI, TRDizin)

15. Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer

Erol V. B., GÖKTAŞ AYDIN S., BİLİCİ A., ÇAKIR A., AÇIKGÖZ Ö., ÖLMEZ Ö. F., et al.

Journal of Chemotherapy , cilt.35, sa.7, ss.662-670, 2023 (SCI-Expanded, Scopus)

16. Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: a multicenter analysis

Acikgoz O., Bilici A., Tataroglu Ozyukseler D., Göktaş Aydın S., Selcukbiricik F., Rzazade R., et al.

Turkish Journal of Medical Sciences , cilt.53, sa.4, ss.949-961, 2023 (SCI-Expanded, Scopus, TRDizin)

17. The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer

Aydin S. G., BİLİCİ A., ÖLMEZ Ö. F., Oven B. B., AÇIKGÖZ Ö., ÇAKIR T., et al.

Breast Care , cilt.17, sa.5, ss.470-479, 2022 (SCI-Expanded, Scopus)

18. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Hizal M., Bilgin B., Paksoy N., AÇIKGÖZ Ö., Sezer A., Gürbüz M., et al.

Journal of Cancer Research and Clinical Oncology , cilt.148, sa.6, ss.1501-1508, 2022 (SCI-Expanded, Scopus)

19. Rare side effect caused by atezolizumab, an immune checkpoint inhibitor: Cold agglutinin disease

AÇIKGÖZ Ö., BAYRAMGİL A., Cavusoglu G., Sadri S.

Journal of Oncology Pharmacy Practice , cilt.27, sa.8, ss.2066-2068, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

20. Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer

AÇIKGÖZ Ö., Cakan B., Demir T., BİLİCİ A., Oven B. B., HAMDARD J., et al.

Medicine (United States) , cilt.100, sa.44, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

21. Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey

Cakan B., AÇIKGÖZ Ö., BİLİCİ A., Demir T., Oven B. B., HAMDARD J., et al.

Journal of B.U.ON. , cilt.26, sa.5, ss.1908-1917, 2021 (SCI-Expanded, Scopus)

22. The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study

Akdeniz N., Kaplan M. A., Uncu D., İNANÇ M., Kaya S., Dane F., et al.

International Journal of Colorectal Disease , cilt.36, sa.6, ss.1311-1319, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

23. Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer

AYDIN S. G., AÇIKGÖZ Ö., KUTLU Y., BİLİCİ A., HAMDARD J., ÖLMEZ Ö. F., et al.

ACTA ONCOLOGICA TURCICA , cilt.54, sa.3, ss.281-290, 2021 (TRDizin)

24. Triple-negative breast cancer presented with metastasis to the heart as first sign of recurrence

BAYRAMGİL A., BİLİCİ A., HAMDARD J., AÇIKGÖZ Ö., ŞEKER M., KILIÇASLAN F., et al.

Breast Journal , cilt.27, sa.1, ss.56-57, 2021 (SCI-Expanded, Scopus)

25. Prognostic Significance of Metastatic Lymph Node Ratio in Patients with pN3 Gastric Cancer Who Underwent Curative Gastrectomy

BİLİCİ A., Selcukbiricik F., ŞEKER M., Oven B. B., ÖLMEZ Ö. F., YILDIZ Ö., et al.

Oncology Research and Treatment , cilt.42, sa.4, ss.204-211, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma